YTEN — Yield10 Bioscience Share Price
Last trade - 00:00- $0.77m
- $0.16m
- $0.06m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.74 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -4352.33% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.81 | 0.8 | 0.61 | 0.45 | 0.06 | 1.2 | 2.6 | -35.94% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Yield10 Bioscience, Inc. is an agricultural bioscience company that is leveraging advanced genetics to develop the oilseed Camelina sativa (Camelina) as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and PHA bioplastics for use as biodegradable bioplastics. The Company is pursuing Camelina seed oil products for two market opportunities and value chains. The first product is seed oil produced by Camelina, which is genetically engineered to enable production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA). The second product is Camelina seed oil for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD) and sustainable aviation fuel (SAF).
Directors
- Robert Van Nostrand NEC (63)
- Oliver Peoples PRE (63)
- Charles Haaser CAO (65)
- Lynne Brum VPR (57)
- Kristi Snell VPR (53)
- Darren Greenfield SDR
- Tichafa Munyikwa OTH
- Nicholas Renegar OTH
- Sherri Brown IND (59)
- Richard Hamilton IND (58)
- Anthony Sinskey IND (81)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- September 1st, 1998
- Public Since
- November 10th, 2006
- No. of Shareholders
- 28
- No. of Employees
- 29
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 642,546
- Address
- 19 Presidential Way Ste 201, WOBURN, 01801-1184
- Web
- https://www.yield10bio.com/
- Phone
- +1 6175831700
- Auditors
- RSM US LLP
Latest News for YTEN
Upcoming Events for YTEN
Q2 2024 Yield10 Bioscience Inc Earnings Release
Q3 2024 Yield10 Bioscience Inc Earnings Release
Similar to YTEN
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 24:15 UTC, shares in Yield10 Bioscience are trading at $1.28. This share price information is delayed by 15 minutes.
Shares in Yield10 Bioscience last closed at $1.28 and the price had moved by -97.18% over the past 365 days. In terms of relative price strength the Yield10 Bioscience share price has underperformed the S&P500 Index by -97.63% over the past year.
The overall consensus recommendation for Yield10 Bioscience is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Yield10 Bioscience does not currently pay a dividend.
Yield10 Bioscience does not currently pay a dividend.
Yield10 Bioscience does not currently pay a dividend.
To buy shares in Yield10 Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.28, shares in Yield10 Bioscience had a market capitalisation of $0.82m.
Here are the trading details for Yield10 Bioscience:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: YTEN
Based on an overall assessment of its quality, value and momentum Yield10 Bioscience is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Yield10 Bioscience is $2.50. That is 95.31% above the last closing price of $1.28.
Analysts covering Yield10 Bioscience currently have a consensus Earnings Per Share (EPS) forecast of -$17.05 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Yield10 Bioscience. Over the past six months, its share price has underperformed the S&P500 Index by -77.43%.
As of the last closing price of $1.28, shares in Yield10 Bioscience were trading -78.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Yield10 Bioscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Yield10 Bioscience's management team is headed by:
- Robert Van Nostrand - NEC
- Oliver Peoples - PRE
- Charles Haaser - CAO
- Lynne Brum - VPR
- Kristi Snell - VPR
- Darren Greenfield - SDR
- Tichafa Munyikwa - OTH
- Nicholas Renegar - OTH
- Sherri Brown - IND
- Richard Hamilton - IND
- Anthony Sinskey - IND